5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
Introduction, cont.
Impact of Culture on HIV and Substance Abuse Epidemics
As other curricula in this series have discussed both the larger majority culture and specific racial and ethnic cultures can have broad impacts on how chronic conditions among diverse populations are prevented and treated. These impacts apply similarly to both the HIV and substance abuse epidemics. Addressing each of them individually and in situations of comorbidity will require healthcare practitioners to take into account the particular cultural factors that are associated with both risk for and protection against HIV infection and substance abuse in African American, Hispanic, Native American, Asian/Pacific Islanders, and other racial/ethnic communities. A host of culturally unique socioeconomic and demographic factors contributes to the choices that individuals make in the behaviors that may increase or decrease their risk for acquiring HIV infection or engaging in substance use, and that may contribute to the continuing health disparities among diverse US population groups. [Amaro 2001]
Standard prevention and treatment paradigms have typically focused on individual pathology, but more productive strategies will need to draw upon a broader paradigm that considers the negative impacts of historical trauma and ongoing discrimination related to diverse ethnic groups. A broader paradigm for providing culturally competent care will further take into account particular cultural groups’ strengths—eg, family and community, spirituality and faith practices, and traditional healing practices. [Walters 2002] Incorporating these factors will be vital to the development of comprehensive, community-based HIV and substance abuse prevention and treatment programs that target African Americans, Hispanics, and diverse other populations that are disproportionately affected by both HIV and substance use.
Public Health Importance of Improving Outcomes in Overlapping HIV and Substance Use Epidemics
Improving public, in addition to individual, health outcomes has long stood as a primary goal in the treatment of both HIV disease and substance use. With both epidemics, providing effective treatment for individual patients also leads to significant public health benefits.
Clear nationwide data concerning the cost benefits associated with substance use treatment are lacking. However, limited research in some states suggests that the benefits are substantial. Recent estimates of the total financial cost of drug use disorders in the United States cite a figure of $180 billion annually [ONDCP 2004], and a report from 2000 estimated the annual economic costs of alcohol abuse as $184.6 billion. [Harwood 2000] These estimates suggest the large reduction of society’s financial burden that can be achieved from accessible, effective alcohol and drug treatment programs. A study by Ettner and colleagues reported that treatment of substance use disorders is associated with a cost-benefit ratio of 1:7—that is, each $1 invested in treatment is associated with future cost reductions of $7, largely due to reduced costs of crime and increased employer earnings. [Ettner 2006]
Similarly, the HPTN 052 Study, a large multinational trial, evaluated the effect on HIV transmission rates in patients receiving earlier vs later initiation of antiretroviral therapy. Cohen and colleagues reported that early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV and HIV-related clinical events and concluded that such an approach to managing HIV patients was associated with both individual and public health benefits.[Cohen 2011] A number of other clinical trials have reported similar outcomes, demonstrating the critical advantages of beginning antiretroviral therapy at higher CD4+ cell counts. [Reynolds 2011, Sterne 2009, Dieffenbach 2009]
Such proven benefits in reducing societal costs and improving both personal and public health in the effective treatment of both HIV disease and substance use underline the importance of addressing the diagnostic and treatments needs of HIV-positive substance users.